Compare BIP & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIP | PODD |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 17.0B |
| IPO Year | N/A | 2007 |
| Metric | BIP | PODD |
|---|---|---|
| Price | $34.60 | $159.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 21 |
| Target Price | $39.50 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 768.1K | 763.3K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | N/A | $24.55 |
| Revenue Next Year | $7.61 | $19.18 |
| P/E Ratio | ★ $39.22 | $52.54 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $29.19 | $182.25 |
| 52 Week High | $40.32 | $354.88 |
| Indicator | BIP | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 35.24 | 13.91 |
| Support Level | $34.69 | N/A |
| Resistance Level | $35.23 | $205.95 |
| Average True Range (ATR) | 0.85 | 6.67 |
| MACD | -0.12 | -1.78 |
| Stochastic Oscillator | 32.02 | 5.49 |
Brookfield Infrastructure Partners LP is a Bermuda exempted limited partnership that owns and operates quality, long-life assets that generate stable cash flows, by virtue of barriers to entry or other characteristics that tend to appreciate in value over time. It focuses on acquiring infrastructure assets that have low maintenance capital costs and high barriers to entry. The company's segments consist of Utilities, Transport, Midstream, and Data. Geographically, it generates maximum revenue from USA and also has a presence in Australia, Colombia, United Kingdom, Brazil, United States of America, Chile, Peru, and other countries.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.